FDA Appoints Frank M. Torti to Senior Leadership Position
Frank M. Torti, MD, has been appointed principal deputy commissioner and first ever chief scientist at the FDA.
Frank M. Torti, MD, has been appointed principal deputy commissioner and first ever chief scientist at the FDA. The newly created chief scientist position stems from the Food and Drug Administration Amendments Act of 2007. As Chief Scientist and a member of the agency’s senior leadership team, Torti will support the launch of the FDA Fellowship Program, a new program that will work to ensure the quality and regulatory focus of the intramural research programs of the agency, and place special emphasis on the importance of clinical research trials.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
